Pimavanserin increases mortality in elderly with Parkinson's disease: Study
According to a new study published in the Journal Neurology, older persons with Parkinson's disease (PD) who used pimavanserin had an increased risk of hospitalization and death at particular time points after initiation compared to nonusers.
This study validates the prior concerns regarding use of pimavanserin and the risks it brings when chosen to use it in case of Parkinson's disease (PD). It also stated the association of typical and atypical antipsychotic drugs with increased death rate in Parkinson's disease (PD) patients.
From November 1, 2015 to December 31, 2018, Hwang and colleagues conducted a retrospective cohort analysis to examine the risk of hospitalization and mortality associated with pimavanserin usage among individuals 65 years and older with Parkinson's disease (PD) .The data was obtained via an administrative dataset on residents of Medicare-certified long-term care facilities and linked Medicare claims data.
The goal of this research was to assess the hazards of pimavanserin [Nuplazid, Acadia Pharmaceuticals], a new antipsychotic licensed for Parkinson's disease psychosis.
The researchers discovered a link between pimavanserin usage and a greater probability of 30-day hospitalisation when compared to non-users. They found no link between pimavanserin usage and 90-day hospitalisation or 30-day death. But they did find a link between pimavanserin use and higher 90-day mortality that lasted for 180 days and a year.
In conclusion, the authors say that Pimavanserin use vs. nonuse in older adults was associated with an increased risk of hospitalization at one month of initiation and a higher risk of death for up to one year following initiation.
The findings of the study might help in taking better decisions with respect to choosing pharmacotherapy for Parkinson's disease (PD) .
Source
Hwang, Y. J., Alexander, G. C., An, H., Moore, T. J., & Mehta, H. B. (2021). Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. Neurology, 10.1212/WNL.0000000000012601. https://doi.org/10.1212/wnl.0000000000012601
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.